Natera, Inc. (NASDAQ:NTRA)’s share price was down 0% during mid-day trading on Thursday following a weaker than expected earnings announcement. The company traded as low as $8.66 and last traded at $9.41. Approximately 528,397 shares were traded during trading, an increase of 298% from the average daily volume of 132,774 shares. The stock had previously closed at $9.41.

The medical research company reported ($0.51) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.04). The business had revenue of $56.66 million for the quarter, compared to the consensus estimate of $55.31 million. Natera had a negative return on equity of 137.46% and a negative net margin of 62.64%. The business’s revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.50) earnings per share.

A number of analysts have recently commented on NTRA shares. Zacks Investment Research lowered Natera from a “buy” rating to a “hold” rating in a report on Thursday, October 26th. BidaskClub upgraded Natera from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. ValuEngine upgraded Natera from a “strong sell” rating to a “sell” rating in a report on Thursday, August 10th. Finally, Morgan Stanley cut their price target on Natera from $18.00 to $13.00 and set an “overweight” rating on the stock in a report on Monday, August 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $16.20.

In other news, insider Jonathan Sheena sold 120,000 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $12.54, for a total value of $1,504,800.00. Following the sale, the insider now directly owns 533,208 shares in the company, valued at $6,686,428.32. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 12.57% of the company’s stock.

Several large investors have recently added to or reduced their stakes in NTRA. Virtu KCG Holdings LLC acquired a new stake in shares of Natera in the second quarter valued at about $126,000. American International Group Inc. increased its position in shares of Natera by 7.1% in the first quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock valued at $142,000 after acquiring an additional 1,068 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Natera in the second quarter valued at about $151,000. Goldman Sachs Group Inc. increased its position in shares of Natera by 45.3% in the first quarter. Goldman Sachs Group Inc. now owns 17,386 shares of the medical research company’s stock valued at $154,000 after acquiring an additional 5,417 shares during the last quarter. Finally, Voya Investment Management LLC increased its position in shares of Natera by 17.8% in the second quarter. Voya Investment Management LLC now owns 14,663 shares of the medical research company’s stock valued at $159,000 after acquiring an additional 2,212 shares during the last quarter. 59.89% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Natera, Inc. (NTRA) Trading Down 0% Following Weak Earnings” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/09/natera-inc-ntra-trading-down-0-following-weak-earnings.html.

Natera Company Profile

Receive News & Stock Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related stocks with our FREE daily email newsletter.